Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2009 May 1;19(9):2537-41. doi: 10.1016/j.bmcl.2009.03.024. Epub 2009 Mar 13.

The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.

Author information

1
Pfizer Global Research and Development, Groton Laboratories, Groton, CT 06340, USA.

Abstract

Starting from a non-selective pyrazolo-pyrimidone lead, the sequential use of parallel medicinal chemistry and directed synthesis led to the discovery of potent, highly selective, and orally bioavailable PDE9 inhibitors. The availability of these tools allowed for a thorough evaluation of the therapeutic potential of PDE9 inhibition.

PMID:
19339180
DOI:
10.1016/j.bmcl.2009.03.024
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center